Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2020. Resilient H1 financial performance : Group sales growth of 3.1% as reported and at constant currency, driven by...
Ipsen ( OTCPK:IPSEY +6.1% ) reacts to share buyback as the company purchased a total of 14,989 shares with an average price of ~$77.26. More news on: Ipsen S.A., Stocks on the move, Healthcare stocks news, Read more ...
Ipsen ( OTCPK:IPSEY ) will join the Exelixis (NASDAQ: EXEL ) and Roche ( OTCQX:RHHBY ) clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III trials. More news on: Ipsen S.A., Exelixis, Inc., Roche Holding AG, Health...
Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib Participation will provide Ipsen access to the respective study results to support potential future regulatory submissions in its territories Regulatory News: Ipsen (Eu...
Ipsen ( OTCPK:IPSEY ) announces data from the primary analysis of a Phase 1/2 clinical trial evaluating the combination of Onivyde (irinotecan liposome injection) and other chemo agents in a regimen called NALIRIFOX in patients with previously untreated, unresectable, locally advanced/me...
Ipsen has initiated the NAPOLI-3 Phase III clinical study (NCT04083235) comparing the safety and efficacy of liposomal irinotecan + 5-fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) (NALIRIFOX) to gemcitabine + nab-paclitaxel in the first-line setting Ipsen has been granted Fast Trac...
The FDA has granted Fast Track designation for Ipsen's ( OTCPK:IPSEY ) investigational use of liposomal irinotecan (ONIVYDE) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) together, known as NALIRIFOX for patients with previously untreated, locally advanced a...
– Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGI) on July 1, 2020 – Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States F...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), announces today that it has appointed an investment services provider to purchase 450,000 Ipsen SA shares, or about 0.54% of the share capital, over a maximum period of 6 months. The shares purchased under this agreement will be mainly a...
Data published evaluates fibrodysplasia ossificans progressiva (FOP) natural disease progression The Natural History Study (NHS) is the first protocol-specified, longitudinal evaluation of FOP disease progression Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), shared data from...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...